Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 121–144 of 180
Gut microbial composition significantly influences individual response to GLP-1 medications, with distinct bacterial patterns correlating to treatment efficacy and the ability of the microbiome to support metabolic signaling. This mechanism explains variable clinical outcomes and suggests microbiome profiling could predict responders before treatment initiation.
Aging T cells develop senescence characteristics that drive chronic inflammatory skin diseases through dysregulated signaling pathways and secretion of pro-inflammatory factors. Targeting senescent T cells or their signaling cascades offers a mechanism-based approach to achieving sustained remission in conditions like psoriasis and atopic dermatitis.
GLP-1 receptor agonists effectively reduce adiposity but simultaneously cause skeletal muscle loss, a consequence that diminishes metabolic efficiency and increases frailty risk in vulnerable populations. Preserving muscle mass during weight loss produces superior long-term metabolic outcomes and functional longevity compared to adiposity reduction alone.
Renue by Science received recognition for its Total NAD+ Restoration Protocol, a multi-pathway supplement approach designed to address age-related NAD+ decline through enhanced precursor delivery, reduced NAD+ catabolism, improved mitochondrial efficiency, and cellular repair support. NAD+ restoration represents a targeted intervention in the metabolic foundation of cellular aging.
Senescent cells—those that have stopped dividing—adopt distinct molecular profiles depending on how they became senescent. Primary senescence (triggered by direct DNA damage) activates fibrosis and tissue-remodeling programs, while secondary senescence (induced by signals from other senescent cells) drives inflammatory pathways. Both share conserved stress-response mechanisms, revealing that senescence heterogeneity fundamentally shapes how these cells contribute to aging.
Mitochondrial dysfunction is increasingly recognized as a central mechanism underlying age-related disease, not merely a feature of rare genetic conditions. The FDA approval of elamipretide (Forzinity) for Barth syndrome represents the first regulatory validation of mitochondria-targeted therapeutics, positioning this class of drugs as potential interventions for common age-related conditions including neurodegeneration and cardiac disease.
Phase 1 data for RLS-1496, a GPX4 modulator, demonstrate safety and dose-dependent target engagement alongside reductions in senescence markers and clinical improvement in inflammatory skin conditions. The drug operates through a dual mechanism: clearing senescent cells via ferroptosis while restoring redox balance in stressed neighboring cells, representing a shift toward cellular recalibration rather than indiscriminate senescent cell clearance.
Methionine restriction extends lifespan in yeast by reducing S-adenosylmethionine production, which prevents methylation of protein phosphatase 2A and triggers sustained autophagy. Early-stage methionine restriction appears sufficient to activate this longevity pathway, suggesting a potential therapeutic target for human healthspan extension without sustained dietary restriction.
Springfield Wellness Center has operated for 25 years using intravenous NAD+ therapy as part of a multimodal protocol for addiction recovery and brain restoration. The clinic's longevity and expansion suggest sustained clinical utility, though the evidence base and mechanistic clarity for NAD+ infusions in longevity contexts remain limited.
Reduced insulin signaling extends lifespan in Drosophila, but the effect—beneficial or detrimental—depends on the genetic interaction between mitochondrial and nuclear DNA. This reveals that conserved aging mechanisms operate differently across individuals based on mito-nuclear epistasis, with direct implications for personalized longevity interventions.
A February 2026 research roundup covering advances in cellular reprogramming, senolytic effectiveness, immune cell restoration, and cognitive interventions demonstrates multiple convergent pathways for addressing age-related decline. The collective findings suggest that aging is modifiable across multiple biological domains, with implications for clinical translation in vision, neurological, and metabolic disease.
A randomized controlled trial of a fasting mimetic formulation in overweight older adults with elevated HbA1c showed reductions in LDL particle number, oxidized LDL, and fasting glucose over eight weeks. The compound—a blend of spermidine, nicotinamide, palmitoylethanolamide, and oleoylethanolamide—reproduced several cardiometabolic signatures associated with fasting without dietary restriction, though durability beyond the study period remains undemonstrated.
This AMA addresses multiple longevity domains: biological aging biomarkers, exercise protocols for longevity, emerging therapeutic approaches, GLP-1 receptor agonists, and sun exposure risk-benefit profiles. The discussion emphasizes that evidence-based interpretation of these tools requires distinguishing between mechanistic plausibility and demonstrated clinical outcomes.
Pharmacological reactivation of HIF-1α signaling in aged satellite cells restores lactate-driven epigenetic remodeling and shifts cells from senescence toward a regenerative state, with treated cells demonstrating enhanced myogenic capacity and increased ATP production. This identifies a metabolic-epigenetic axis relevant to age-related muscle decline and suggests a therapeutic target for sarcopenia.
Inhibiting the ghrelin receptor (GHSR-1a) improves muscle strength, exercise capacity, and mitochondrial function in aging mice, reducing sarcopenia markers without extending lifespan. Pharmacological inhibition via PF-5190457 replicates these effects and represents a translatable therapeutic approach.
This correction addresses a published study on how senescent cells reorganize their chromatin architecture in response to therapeutic stress. Understanding the structural changes in non-dividing cells has direct implications for improving cellular resilience and longevity through better therapeutic design.
PGC-1α, a transcriptional coactivator that regulates cellular energy metabolism and mitochondrial biogenesis, is emerging as a target for age-related disease intervention. Endurance Bio is advancing a small molecule (T-168) designed to upregulate PGC-1α, with Phase 2 trials underway in Parkinson's disease and potential applications across neurodegeneration, metabolic dysfunction, and frailty.
Natural killer cells from older adults show reduced capacity to eliminate senescent and cancer cells due to impaired granule release and cytotoxic machinery, not recognition defects. Targeting elevated Cdc42 protein and restoring microtubular organization represents a potential intervention to restore NK cell function with age.
Senescent hepatocytes in aging release extracellular vesicles containing microRNAs that enhance metastatic potential across multiple cancer types in aged organisms. This mechanism directly links hepatic aging to systemic cancer progression, identifying a previously uncharacterized pathway connecting liver dysfunction to increased metastatic risk in older adults.
Senescent cells accumulate with age and suppress antiviral immunity through four secreted factors—GDF15, IGF1, IL1α, and IL6—via two distinct signaling pathways. Blocking these factors restores innate antiviral defense in aged mice, offering a mechanistic target to improve immune resilience against infection in older adults.
Senescent macrophages expressing p21 and TREM2 accumulate with age and drive chronic inflammation and metabolic dysfunction in the liver. This identification of a specific senescent immune cell phenotype directly connects cellular aging to systemic metabolic decline and suggests a mechanistic target for interventions addressing age-related disease.
Cellular senescence in ectopic endometrial tissue drives aggressive endometriosis through a PAK4/AKT signaling loop that promotes macrophage-mediated immune remodeling. Stigmasterol, a plant-derived phytosterol, suppresses this pathway and reduces lesion invasiveness in preclinical models, suggesting a mechanism-based therapeutic approach to a senescence-driven disease subtype.
SIRT6, a sirtuin protein, protects against neurodegenerative diseases by maintaining nucleolar function and constraining protein synthesis, preventing the accumulation of misfolded proteins that drives age-related brain pathology. This mechanism represents a direct intervention point in proteostasis failure, a primary driver of cognitive decline.
Aged male mice maintain glucose tolerance despite accumulating more fat on a high-fat diet than younger counterparts, a metabolic uncoupling driven by increased energy storage efficiency and reduced lipid turnover. This finding indicates that obesity and glucose dysregulation diverge with age, presenting distinct intervention targets for metabolic health in older populations.
